Learn about the measures we're taking to ensure your safety and other information about cancer and the coronavirus.

In 2017, the FDA approved the first cellular therapy for cancer, a living drug called Kymriah, developed at Penn by Dr. Carl June. Learn more about the significance of this new therapy and other revolutionary research being conducted at Penn

Dahlia Sataloff, MD, FACS, is a Professor of Clinical Surgery and the Chair of Surgery at Pennsylvania Hospital. To learn more about her work, career and motivations, read our interview with Dr. Sataloff.

With advancements in immunotherapy, radiation therapy and surgical resection, Penn Medicine is making progress towards a life-extending treatment for the aggressive brain cancer, glioblastoma.